Red de Bibliotecas Virtuales de Ciencias Sociales en
América Latina y el Caribe

logo CLACSO

Por favor, use este identificador para citar o enlazar este ítem: https://biblioteca-repositorio.clacso.edu.ar/handle/CLACSO/169116
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorKeita, A.-
dc.creatorFranetich, J. F.-
dc.creator/Carraz, Maëlle-
dc.creatorValentin, L.-
dc.creatorBordessoules, M.-
dc.creatorBaron, L.-
dc.creatorBigeard, P.-
dc.creatorDupuy, F.-
dc.creatorGeay, V.-
dc.creatorTefit, M.-
dc.creatorSarrasin, V.-
dc.creatorMichel, S.-
dc.creatorLavazec, C.-
dc.creatorHouze, S.-
dc.creatorMazier, D.-
dc.creatorSoulard, V.-
dc.creatorPoree, F. H.-
dc.creator/Duval, Romain-
dc.date2022-
dc.date.accessioned2022-04-27T17:37:50Z-
dc.date.available2022-04-27T17:37:50Z-
dc.identifierhttps://www.documentation.ird.fr/hor/fdi:010084410-
dc.identifieroai:ird.fr:fdi:010084410-
dc.identifierKeita A., Franetich J. F., Carraz Maëlle, Valentin L., Bordessoules M., Baron L., Bigeard P., Dupuy F., Geay V., Tefit M., Sarrasin V., Michel S., Lavazec C., Houze S., Mazier D., Soulard V., Poree F. H., Duval Romain. Potent antiplasmodial derivatives of dextromethorphan reveal the ent-morphinan pharmacophore of tazopsine-type alkaloids. 2022, 14 (2), p. 372 [23 p.]-
dc.identifier.urihttp://biblioteca-repositorio.clacso.edu.ar/handle/CLACSO/169116-
dc.descriptionThe alkaloid tazopsine 1 was introduced in the late 2000s as a novel antiplasmodial hit compound active against Plasmodium falciparum hepatic stages, with the potential to develop prophylactic drugs based on this novel chemical scaffold. However, the structural determinants of tazopsine 1 bioactivity, together with the exact definition of the pharmacophore, remained elusive, impeding further development. We found that the antitussive drug dextromethorphan (DXM) 3, although lacking the complex pattern of stereospecific functionalization of the natural hit, was harboring significant antiplasmodial activity in vitro despite suboptimal prophylactic activity in a murine model of malaria, precluding its direct repurposing against the disease. The targeted N-alkylation of nor-DXM 15 produced a small library of analogues with greatly improved activity over DXM 3 against P. falciparum asexual stages. Amongst these, N-2 '-pyrrolylmethyl-nor-DXM 16i showed a 2- to 36-fold superior inhibitory potency compared to tazopsine 1 and DXM 3 against P. falciparum liver and blood stages, with respectively 760 +/- 130 nM and 2.1 +/- 0.4 mu M IC50 values, as well as liver/blood phase selectivity of 2.8. Furthermore, cpd. 16i showed a 5- to 8-fold increase in activity relative to DXM 3 against P. falciparum stages I-II and V gametocytes, with 18.5 mu M and 13.2 mu M IC50 values, respectively. Cpd. 16i can thus be considered a promising novel hit compound against malaria in the ent-morphinan series with putative pan cycle activity, paving the way for further therapeutic development (e.g., investigation of its prophylactic activity in vivo).-
dc.languageEN-
dc.subjectmalaria-
dc.subjectPlasmodium berghei-
dc.subjectPlasmodium falciparum-
dc.subjecthepatic stages-
dc.subjectblood stages-
dc.subjectprophylaxis-
dc.subjecttazopsine-
dc.subjectdextromethorphan-
dc.subjectN-alkylation-
dc.subjecthit compound-
dc.titlePotent antiplasmodial derivatives of dextromethorphan reveal the ent-morphinan pharmacophore of tazopsine-type alkaloids-
dc.typetext-
Aparece en las colecciones: Institut de Recherche pour le Développement - IRD - Cosecha

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.